V-125

V-125 is a next-generation, selective retinoid X receptor (RXR) agonist (rexinoid) engineered to provide enhanced transcriptional activity and improved safety compared to first-generation agonists like bexarotene. It is designed to minimize lipogenic side effects, such as hypertriglyceridemia, which are common with earlier RXR ligands. In preclinical studies of HER2-positive breast cancer, V-125 has shown potent anti-tumor activity by inducing distinct transcriptional programs and modulating the tumor microenvironment. Specifically, it promotes the infiltration of CD8+ T cells and reduces the presence of immunosuppressive CD206+ macrophages, suggesting a role in enhancing anti-tumor immunity alongside its direct effects on cancer cell growth.